Contrasting actions of selective inhibitors of angiopoietin-1 and angiopoietin-2 on the normalization of tumor blood vessels - sprookjes - yvandenbroek - TriplyDB

Contrasting actions of selective inhibitors of angiopoietin-1 and angiopoietin-2 on the normalization of tumor blood vessels

Contrasting actions of selective inhibitors of angiopoietin-1 and angiopoietin-2 on the normalization of tumor blood vessels

http://www.wikidata.org/entity/Q24644150

about

PI3K/AKT/mTOR Pathway in Angiogenesis Methylseleninic acid restricts tumor growth in nude mice model of metastatic breast cancer probably via inhibiting angiopoietin-2 Tumour progression and metastasis Molecular control of capillary morphogenesis and maturation by recognition and remodeling of the extracellular matrix: functional roles of endothelial cells and pericytes in health and disease Cancer-stromal cell interactions mediated by hypoxia-inducible factors promote angiogenesis, lymphangiogenesis, and metastasis Profile of trebananib (AMG386) and its potential in the treatment of ovarian cancer Receptor tyrosine kinase-mediated angiogenesis Emerging roles of pericytes in the regulation of the neurovascular unit in health and disease Angiopoietin-Tie signalling in the cardiovascular and lymphatic systems Molecular mechanisms and clinical applications of angiogenesis Vascular normalization as a therapeutic strategy for malignant and nonmalignant disease.Normalization of the vasculature for treatment of cancer and other diseases.A novel angiopoietin-2 selective fully human antibody with potent anti-tumoral and anti-angiogenic efficacy and superior side effect profile compared to Pan-Angiopoietin-1/-2 inhibitors.Acute tumour response to a bispecific Ang-2-VEGF-A antibody: insights from multiparametric MRI and gene expression profiling.Peptibodies: A flexible alternative format to antibodies.Angiopoietin-2 interferes with anti-VEGFR2-induced vessel normalization and survival benefit in mice bearing gliomas.Complementary actions of inhibitors of angiopoietin-2 and VEGF on tumor angiogenesis and growth.Direct endothelial junction restoration results in significant tumor vascular normalization and metastasis inhibition in mice The role of angiopoietins as potential therapeutic targets in renal cell carcinoma.Increased vascular delivery and efficacy of chemotherapy after inhibition of platelet-derived growth factor-B Targeting lymphatic vessel functions through tyrosine kinases.Identification of serum angiopoietin-2 as a biomarker for clinical outcome of colorectal cancer patients treated with bevacizumab-containing therapy Evaluation of tumor microenvironment in an animal model using a nanoparticle contrast agent in computed tomography imaging Angiopoietin-1/Tie2 signal augments basal Notch signal controlling vascular quiescence by inducing delta-like 4 expression through AKT-mediated activation of beta-catenin Inhibition of angiopoietin-2 in LuCaP 23.1 prostate cancer tumors decreases tumor growth and viability.Pericyte requirement for anti-leak action of angiopoietin-1 and vascular remodeling in sustained inflammation Angiopoietins modulate endothelial adaptation, glomerular and podocyte hypertrophy after uninephrectomy.Circulating Ang-2 mRNA expression levels: looking ahead to a new prognostic factor for NSCLC [corrected]Anti-vascular therapies in ovarian cancer: moving beyond anti-VEGF approaches.Angiopoietin-2, an angiogenic regulator, promotes initial growth and survival of breast cancer metastases to the lung through the integrin-linked kinase (ILK)-AKT-B cell lymphoma 2 (Bcl-2) pathway Context-dependent role of angiopoietin-1 inhibition in the suppression of angiogenesis and tumor growth: implications for AMG 386, an angiopoietin-1/2-neutralizing peptibody.Vasculotide reduces endothelial permeability and tumor cell extravasation in the absence of binding to or agonistic activation of Tie2.Effects of angiopoietin-2-blocking antibody on endothelial cell-cell junctions and lung metastasis A novel angiopoietin-derived peptide displays anti-angiogenic activity and inhibits tumour-induced and retinal neovascularization.The complex role of angiopoietin-2 in the angiopoietin-tie signaling pathway.PV1 down-regulation via shRNA inhibits the growth of pancreatic adenocarcinoma xenografts.Inhibition of the angiopoietin/Tie2 axis induces immunogenic modulation, which sensitizes human tumor cells to immune attack.Endothelial cell-derived angiopoietin-2 is a therapeutic target in treatment-naive and bevacizumab-resistant glioblastoma.Prognostic value of angiopoietin-2 for death risk stratification in patients with metastatic colorectal carcinoma.Development and characterization of a high-throughput in vitro cord formation model insensitive to VEGF inhibition.

P2860

Q21129332-0E8D33BE-540F-4627-A9BD-4EE4759785BB Q21261285-9DC3537C-FEEB-4DBA-B693-A5CB5CA7D9A3 Q26766468-751324DF-6D6D-4C2B-8C9B-F502A37293C0 Q26797500-68F65085-29C2-4B06-B568-B80529908CE9 Q26866144-66A62F40-F1B6-4FAB-A8DF-F0AFEAA9B935 Q26991997-8AD8FEBD-B8AB-427B-8B82-111D5E8F4C71 Q27001612-E5CDCF5F-C61B-4E36-840E-FAF4D0C64DBD Q27011505-E70ED3BE-1FD3-43FC-9A9A-05866533DB4C Q28070234-C43FD0EF-D555-4BC3-8D0D-F9C9620AC05A Q29547314-7A7247A1-6A99-4FF5-94EA-DCC0C0513C6D Q30469815-05FDCF59-6175-4B05-8B5B-9F6844496E26 Q30471456-3E2446CA-6CF4-4343-857A-76292BEB1461 Q31110832-8177E96C-1192-475B-AE31-B56AC12B5577 Q31121875-A553DA63-455D-41B1-BFEE-6A144C023B4A Q33402480-0F526739-9B26-45CF-9CFB-452C72E2B83B Q33587106-A19BFD1B-F892-42BF-858B-39005C7EDEEC Q33732486-447A2FC6-0733-434A-8A30-09E4AB44A52B Q33757106-9DC036EB-73AF-4A7C-9E81-9AA24308189A Q33912405-76D3A02E-65AB-4EF9-BB90-2615BA2AEA10 Q33922852-0511BD2A-2674-48FC-A016-3B71FC749A23 Q34078275-53DF9162-9424-4FE4-A617-04B42259C846 Q34344165-BE5F8E9D-0917-423B-AF5B-039FD98E6BA7 Q34470473-4D710DCF-87AF-4AC5-A8F2-FC7C097AB627 Q34624256-363CE232-B466-4DA6-981E-6FCC2DC32B62 Q35014686-C09B7CF3-C204-4D74-9E1F-FFEF6088DE55 Q35071289-2FB7ED2E-26A8-44CF-8B9E-FC8222C1D295 Q35075339-DCDAD555-241E-4529-A9C6-E3AF53CCFC85 Q35108561-DDB183BB-EA2B-4CD0-8F30-8AB685C9EA18 Q35205410-D944777B-3AA9-4690-8D49-62F47895A74F Q35310168-2C7C34B4-8FEF-42E0-9763-BCCBC5BFA0DB Q35604097-1A578ECD-0B45-46E8-A02E-120859D31CCB Q35695381-152C04B5-8EE3-4E76-B282-66748F9E21CD Q35842980-DEBB110B-E2E0-4933-85BE-476ED0937D12 Q36025388-9AC61D08-6FA3-46EF-80A1-5189E40A1326 Q36186523-FE9A46DA-E994-487B-92BF-B04E1B13558C Q36213620-1E29F53D-26D9-438C-BBC5-14BF2EF94F7D Q36286833-D81C7151-2808-4FED-A8CB-B81854E25CA4 Q36477818-63376ABC-5FF4-4154-8B1F-10594B3D842B Q36724011-821BBD3A-1A00-4059-B495-EE024CD2EA39 Q36828050-59BA2383-301E-43F9-8048-1733721E7847

P2860

Contrasting actions of selective inhibitors of angiopoietin-1 and angiopoietin-2 on the normalization of tumor blood vessels

http://www.wikidata.org/entity/Q24644150

description

2009 nî lūn-bûn

@nan

2009 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Contrasting actions of selecti ...... ization of tumor blood vessels

@ast

Contrasting actions of selecti ...... ization of tumor blood vessels

@en

Contrasting actions of selecti ...... ization of tumor blood vessels

@nl

type

label

Contrasting actions of selecti ...... ization of tumor blood vessels

@ast

Contrasting actions of selecti ...... ization of tumor blood vessels

@en

Contrasting actions of selecti ...... ization of tumor blood vessels

@nl

prefLabel

Contrasting actions of selecti ...... ization of tumor blood vessels

@ast

Contrasting actions of selecti ...... ization of tumor blood vessels

@en

Contrasting actions of selecti ...... ization of tumor blood vessels

@nl

P1433

Q24644150-A295F3AC-8105-4AB5-A621-591969A693B8

P1476

Q24644150-D9BC839A-0CFC-4BDF-AC61-F3D015AD0FE2

P2093

Q24644150-0C4958BD-B344-4417-BDE2-180E7D898AEB

Q24644150-2752DC89-2ED8-4354-9FF6-5CECB821C200

Q24644150-824F9F9A-050A-4A84-B6E8-15BFD1D93EAD

Q24644150-832B690E-90FD-453D-8AC7-F1FB25C78E29

Q24644150-9B2BCD16-8C4B-4F59-B772-BAF806ADFB7C

Q24644150-A4F33DD2-47A5-42D8-8A4C-D7E68AC5C4A7

Q24644150-B18B51C9-142A-4B64-AA6B-06A53669DFB9

P2860

Q24644150-0AD304B2-068E-4CEB-BE75-22A124DE64CB

Q24644150-0EEE6361-13A0-4CC1-829A-4A20C3C6593E

Q24644150-185276C3-0FBD-4180-8933-CA1C451D1F3B

Q24644150-2408A666-0356-4108-A8BC-2BFAFD67C45F

Q24644150-33E16BDC-9DA7-4E43-BC1F-420856AC12D0

Q24644150-3585C7AF-AC3D-498E-BFC6-F44BF063DFF4

Q24644150-46FC589C-6A90-437E-8FFE-83F5A05BFC73

Q24644150-4E60893A-F2DF-4185-B173-A521D65A15C0

Q24644150-50699034-0A7B-49EF-82C0-3594D7F2E6BB

Q24644150-52BA471F-A328-45B9-B32C-CA825E3FD9D5

P304

Q24644150-D677AB76-CC6C-4E54-B248-96E7ACC7ADB4

P31

Q24644150-66D4067A-EC3B-45B6-986F-616DA09688A7

P3181

Q24644150-9FABCCD5-0FB0-4DA9-AA4C-5BC0A8FDEFC6

P356

Q24644150-4D1DD25E-009A-43E3-8DDF-A946FB14B8D3

P407

Q24644150-3359726D-477E-4BEE-9046-CF0114E9B4CB

P433

Q24644150-018B89C1-16EE-4AD9-B4DF-60B1E83C7543

P478

Q24644150-67A2307C-6ED4-4A17-B559-7D5C8D8E7F27

P50

Q24644150-11F261B2-A6F8-4C10-AEDA-E3FE871D611A

P577

Q24644150-94B9C97D-E9AD-431C-9DD0-486A683DDF39

P5875

Q24644150-7CE974BB-8A69-46C6-97F9-01DA8C472EA6

P698

Q24644150-F9266DE8-66F5-4B4B-A734-C7A4329293B1

P932

Q24644150-5427E906-3F12-44AC-B594-52650FBB6D44

P3181

P356

AJPATH.2009.090391

P1433

The American Journal of Pathology

P1476

Contrasting actions of selecti ...... ization of tumor blood vessels

@en

P2093

Angela Coxon

http://www.w3.org/2001/XMLSchema#string

Beverly L Falcón

http://www.w3.org/2001/XMLSchema#string

Donald M McDonald

http://www.w3.org/2001/XMLSchema#string

Hiroya Hashizume

http://www.w3.org/2001/XMLSchema#string

James V Bready

http://www.w3.org/2001/XMLSchema#string

Jeyling Chou

http://www.w3.org/2001/XMLSchema#string

Jonathan D Oliner

http://www.w3.org/2001/XMLSchema#string

P2860

Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning

Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis

Functionally specialized junctions between endothelial cells of lymphatic vessels

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

Signal transduction pathways mediated by PECAM-1: new roles for an old molecule in platelet and vascular cell biology

Angiopoietin-1 and angiopoietin-2 share the same binding domains in the Tie-2 receptor involving the first Ig-like loop and the epidermal growth factor-like repeats

Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis

Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2

Inhibition of tumor angiogenesis using a soluble receptor establishes a role for Tie2 in pathologic vascular growth

Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy

P304

2159-2170

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

4064878

http://www.w3.org/2001/XMLSchema#string

P356

10.2353/AJPATH.2009.090391

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

175

http://www.w3.org/2001/XMLSchema#string

P50

Petros Koumoutsakos

P577

2009-10-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

26881681

http://www.w3.org/2001/XMLSchema#string

P698

19815705

http://www.w3.org/2001/XMLSchema#string

P932

2774078

http://www.w3.org/2001/XMLSchema#string